High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

Heart

Volumn 100, Issue 11, 2014, Pages 855-861

  Tomaszewski, Maciej ^a,b   White, Christobelle ^a,b   Patel, Prashanth ^c   Masca, Nicholas ^a,b   Damani, Ravi ^a   Hepworth, Joanne ^c   Samani, Nilesh J ^a,b   Gupta, Pankaj ^a,c   Madira, Webster ^c   Stanley, Adrian ^a,c   Williams, Bryan ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Leicester NIHR Biomedical Research Unit in Cardiovascular Disease   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BISOPROLOL; CANDESARTAN; DILTIAZEM; ENALAPRIL; FELODIPINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LABETALOL; LACIDIPINE; LERCANIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PROPRANOLOL; QUINAPRIL; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG URINE LEVEL; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; URINALYSIS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHROMATOGRAPHY, LIQUID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84900302482     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305063     Document Type: Article

References (22)

1. Steiner JF. Rethinking adherence. Ann Intern Med 2012;157:580-5
2. Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. BMJ 2012;345: e7473
3. Myat A, Redwood SR, Qureshi AC, et al. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv 2013;6:184-97
4. Perreault S, Yu AY, Côté R, et al. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology 2012;79:2037-43
5. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29:610-18
6. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
7. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-17
8. Tomaszewski M, Lacka B, Zukowska-Szczechowska E, et al. The evaluation of hypertensive patients' adherence to the pharmacological treatment of hypertension. Wiad Lek 1999;52:573-80
9. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation 2009;120:1558-660
10. Santschi V, Rodondi N, Bugnon O, et al. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med 2008;19:427-34
11. van Onzenoort HA, Verberk WJ, Kroon AA, et al. Electronic monitoring of adherence, treatment of hypertension, and blood pressure control. Am J Hypertens 2012;25:54-9
12. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-74
13. Nuesch R, Schroeder K, Dieterle T, et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ 2001;323:142-6
14. Persu A, Renkin J, Thijs L, et al. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012;60:596-606
15. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81
16. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9
17. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012;30:837-41
18. Mahfoud F, Lüscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34:2149-57
19. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507-10
20. Fitzgerald RL, Rivera JD, Herold DA. Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry. Clin Chem 1999;45:1224-34
21. Murray GJ, Danaceau JP. Simultaneous extraction and screening of diuretics, beta-blockers, selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3857-64
22. Mazzarino M, de la Torre X, Botrè F. A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Anal Bioanal Chem 2008;392:681-98